This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer Reports Top-line Results From Postherpetic Neuralgia And Painful Diabetic Peripheral Neuropathy Lyrica® Studies Conducted In China

Pfizer Inc. (NYSE:PFE) announced today top-line results from two placebo-controlled studies conducted in China with Lyrica ® (pregabalin) in patients with postherpetic neuralgia (pain after shingles or PHN) and painful diabetic peripheral neuropathy (pDPN), respectively. The PHN Phase 4 study, A0081276, met its primary endpoint by demonstrating a statistically significant reduction in pain when compared to placebo. Separately, the pDPN Phase 3 study, A0081265, did not meet its primary endpoint, a statistically significant change in endpoint mean pain score relative to placebo.

The PHN study was an eight-week, randomized, double-blind, multi-center, placebo-controlled, post-marketing study evaluating the efficacy, safety and tolerability of pregabalin 300mg/day in the treatment of subjects with PHN. For the primary efficacy parameter, change from baseline in weekly mean pain scores (0-10 numeric rating scale), a significant treatment difference of -0.71 points for pregabalin relative to placebo was observed (p=0.0002). The safety profile in this study was consistent with the known profile for Lyrica. The most common adverse events reported for subjects given Lyrica were dizziness, oedema peripheral, dry mouth and somnolence.

PHN is a type of peripheral neuropathic pain caused by nerve damage. PHN symptoms include continued burning or electric shock-like pain. 1

The pDPN study was a 11-week randomized, double-blind, multi-center, placebo-controlled study evaluating the efficacy, safety and tolerability of pregabalin 300 mg/day in the treatment of subjects with pDPN. For the primary efficacy parameter, endpoint mean pain score (0-10 numeric rating scale), a treatment difference of -0.28 points for pregabalin relative to placebo was observed (p=0.0559). The safety profile of pregabalin in this study was consistent with the known profile for Lyrica. The most common adverse events reported by subjects given Lyrica were dizziness and somnolence.

pDPN is a form of permanent nerve damage characterized by burning, shooting, pins-and-needles pain in the feet and hands 2.

Full results for both studies will be submitted for publication when analyses are complete.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs